Although most people tolerate Avandaryl well, the medication can cause reactions such as headaches, low blood sugar, and fluid retention. In many cases, side effects are minor and easy to treat. However, there are several side effects of Avandaryl that you should report immediately to your healthcare provider, including trouble breathing, a rapid increase in weight, and vision changes.
In September 2010, the U.S. Food and Drug Administration (FDA) announced that it was severely restricting the use of Avandaryl, due to the risk of "cardiovascular events" such as heart attacks and strokes. Only individuals who could not control their diabetes on other medications (or those who were already taking the medication and doing well) would be able to take Avandaryl.
However, in November 2013, the FDA announced that a careful analysis of the research suggests that there is not, in fact, any increased risk, compared to treatment with standard diabetes medications and that the use of this medication will no longer be restricted.
An Introduction to Avandaryl Side Effects
As with any medicine, there are possible side effects with Avandaryl® (rosiglitazone and glimepiride). However, not everyone who takes Avandaryl will experience side effects. In fact, most people tolerate the drug well. When side effects do occur, in most cases they are minor and either require no treatment or can be treated easily by you or your healthcare provider.
(The side effects discussed below are not a complete list of side effects reported with Avandaryl. Your healthcare provider can discuss a more complete list of possible side effects with you.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Avandaryl [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2011 February.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines (November 25, 2013). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm. Accessed December 20, 2013.
Food and Drug Administration, Center for Drug Evaluation and Research. Avandia (rosiglitazone): REMS - risk of cardiovascular events (9/23/2010). FDA Web site. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226994.htm. Accessed October 1, 2010.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click